Oncological outcomes of parotid gland malignancies: a retrospective analysis of 74 patients

Molteni, Gabriele; Molinari, Giulia; Ghirelli, Michael; Sprio, Andrea Elio; Berta, G.; Malagoli, Andrea; Marchioni, Daniele; Presutti, Livio

doi:10.1016/j.jormas.2019.03.006

Cited by 5 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study demonstrated that the 5‐year OS and DFS among patients with PGC who underwent curative treatment were 73.1% and 62.8%, respectively. These rates were previously reported to be 46% to 82.9% 1,3‐6,21–24 and 60.2% to 74.4%, 3–5,25 respectively; our results are consistent with those of previous studies, given that the treatment protocol at our institution is based on the National Comprehensive Cancer Network guidelines for head and neck cancers 26…”

Section: Discussionsupporting

confidence: 93%

Prognostic Value of the Lymphocyte‐to‐Monocyte Ratio in Patients with Parotid Gland Carcinoma

et al. 2020

View full text Add to dashboard Cite

Objective Previous studies have evaluated various markers as prognostic predictors in patients with many types of cancers. However, the influence of such factors on the outcomes of patients with parotid gland carcinoma (PGC) is unknown. This study investigated the roles of alternative markers in the prognoses of patients with PGC. Methods Overall, 101 patients who underwent curative treatment for PGC were retrospectively evaluated, and their 5‐year overall and disease‐free survival rates were calculated. The prognostic values of clinical and pathologic factors were determined. Results The 5‐year overall and disease‐free survival rates were 73.1% and 62.8%, respectively. Multivariate analysis revealed that a low lymphocyte‐to‐monocyte ratio (LMR), high T classification, high N classification, and perineural invasion were independent predictors of poor prognosis. Conclusions Thus, we identified LMR as an independent prognostic factor for patients with PGC. Patients with low LMRs who are amenable to treatment may require adjuvant treatment to improve their prognoses. Level of Evidence 4 Laryngoscope, 131:E864–E869, 2021

show abstract

Section: Discussionsupporting

confidence: 93%

Prognostic Value of the Lymphocyte‐to‐Monocyte Ratio in Patients with Parotid Gland Carcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that age is an important prognostic factor for survival in patients with PANOS ( 8 , 21 ), and our study also found that younger patients had a better prognosis. In our study, age was an independent prognostic factor of OS and other cause-specific death, but it had no effect on CSS.…”

Section: Discussionsupporting

confidence: 84%

Establishment and Validation of Prognostic Nomograms for Patients With Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 to 2016

Wang

Xiang

2022

Front. Surg.

View full text Add to dashboard Cite

Background: Parotid gland adenocarcinoma not otherwise specified (PANOS) is a rare malignant tumor with limited data on its characteristics and prognosis. This research is aimed at characterizing PANOS and developing prognostic prediction models for patients with PANOS.Methods: Cases from 2004–2016 were selected from the Surveillance, Epidemiology, and End Results (SEER) Program database. Univariate and multivariate Cox regression were applied to ascertain the factors associated with survival. Competing risk analysis and Gray's tests were employed to analyze cancer-specific death. Propensity score matching (1:1) was conducted to reduce the influence of confounding variables.Results: A total of 446 patients with a median age of 66 years were selected, of which 307 were diagnosed with stage III/IV PANOS. The 5-year overall survival (OS) rate of all patients was 51.8%, and the median survival time was 66 months. Surgical treatment clearly improved survival time (p < 0.001). In the subgroup analysis, radiotherapy showed survival benefits in patients with stage III/IV disease (p < 0.001). Multivariate Cox regression analyses showed that age, T classification, N classification, M classification and surgery were independent prognostic indicators for OS; T classification, N classification, M classification and surgery were independent risk factors for cancer-specific survival (CSS). In addition, age was independently associated with other cause-specific death. Based on the results of multivariate analysis, two nomograms were developed and verified by the concordance index (C-index) (0.747 and 0.780 for OS and CSS) and the area under the time-dependent receiver operating characteristic (ROC) curve (0.756, 0.764, and 0.819 regarding for nomograms predicting 3-, 5-, and 10- year OS, respectively and 0.794, 0.789, and 0.806 for CSS, respectively).Conclusions: Our study clearly presents the clinicopathological features and survival analysis of patients with PANOS. In addition, our constructed nomogram prediction models may assist physicians in evaluating the individualized prognosis and deciding on treatment for patients.

show abstract

“…In our study, the median survival of all patients was 66 months. The 5-year and 10-year OS rates were 51.8% and 36.7%, respectively, which were lower than those of mucinous epithelial carcinoma and adenoid cystic carcinoma [12][13] . In our study, some clinical features of PANOS were also in agreement with previously published ndings, including a higher number of males, a propensity for high-grade tumors and more patients who presented with advanced stage III/IV disease [5,12−13] .…”

Section: Discussionmentioning

confidence: 72%

“…Most published reports have focused on the overall assessment of parotid gland carcinomas due to the paucity of patients [11][12][13] . Li et al and Deng et al summarized the clinicopathologic features of PANOS only in few cases [5,7] .…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of Prognostic Nomograms for Patients with Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 To 2016

Wang

Xiang

2021

Preprint

View full text Add to dashboard Cite

Background Parotid gland adenocarcinoma not otherwise specified (PANOS) is a rare malignancy, and the characteristics and prognosis of this disease remain unclear. This study aims to characterize PANOS and establish prognostic prediction models for patients with PANOS. Methods Cases from 2004–2016 were retrieved from the Surveillance, Epidemiology, and End Results Program database (SEER database). Univariate and multivariate Cox regression analyses, Gray's test and propensity score matching (PSM) were conducted to analyze demographics, treatments, and survival outcomes . Results The 446 patients ( 289 men) selected for analysis had a median age of 66 (19–95) years, and 307 patients were diagnosed with stage III/IV disease. The median survival of all patients was 66 months, with a 51.8% 5-year overall survival (OS) rate. Surgical treatment clearly improved survival time (p < 0.001). In the subgroup analysis, radiotherapy showed survival benefits in patients with advanced-stage disease (III/IV) (p < 0.001). Multivariate Cox regression analyses revealed that age, T stage, N stage, M stage and surgery were independent prognostic indicators for OS;T stage, N stage, M stage and surgery were independent risk factors for cancer-specific survival(CSS).In addition, age was independently associated with noncancer-related death. Two nomograms were established based on the results of the multivariate analysis, which was validated by the concordance index (C-index) (0.747 and 0.780 for OS and CSS, respectively) and the area under the time-dependent receiver operating characteristic(ROC) curve(0.756, 0.764 and 0.819 regarding for nomograms predicting 3-, 5- and 10- year OS, respectively and 0.794, 0.789 and 0.806 for CSS, respectively). Conclusions Our study clearly presents the clinicopathological characteristics and survival analysis of patients with PANOS. In addition, our constructed nomogram prediction models may assist physicians in evaluating the individualized prognosis and deciding on treatment for patients.

show abstract

Oncological outcomes of parotid gland malignancies: a retrospective analysis of 74 patients

Cited by 5 publications

References 29 publications

Prognostic Value of the Lymphocyte‐to‐Monocyte Ratio in Patients with Parotid Gland Carcinoma

Prognostic Value of the Lymphocyte‐to‐Monocyte Ratio in Patients with Parotid Gland Carcinoma

Establishment and Validation of Prognostic Nomograms for Patients With Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 to 2016

Development and Validation of Prognostic Nomograms for Patients with Parotid Gland Adenocarcinoma Not Otherwise Specified: A SEER Analysis From 2004 To 2016

Contact Info

Product

Resources

About